GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (FRA:9OF) » Definitions » Short Percentage of Float

BioRestorative Therapies (FRA:9OF) Short Percentage of Float


View and export this data going back to 2021. Start your Free Trial

What is BioRestorative Therapies Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of BioRestorative Therapies's Short Percentage of Float

For the Biotechnology subindustry, BioRestorative Therapies's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioRestorative Therapies's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's Short Percentage of Float falls into.


BioRestorative Therapies Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (FRA:9OF) » Definitions » Short Percentage of Float
Comparable Companies
FBRX ENZN SLXN GLYC KPRX VIRX KTRA JAGX PMCB IKT OCSE:NOVO B REGN VRTX ASX:CSL XKRX:207940 ALNY XBRU:UCB XKRX:068270 MRNA XBRU:ARGX
Traded in Other Exchanges
BRTX:USA 9OF:Germany
Address
40 Marcus Drive, Suite One, Melville, NY, USA, 11747
Website
https://www.biorestorative.com
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

BioRestorative Therapies Headlines

No Headlines